Revlimid – the key concern for Dr Reddy’s is due to the drug’s patent expiry in January 2026, paving the way for competition from generic makers and reduced prices.
Hyderabad-based Dr Reddy’s Laboratories is expected to post positive top-line and profit figures in the upcoming first-quarter results scheduled for announcement on July 23. While some brokerages are bearish regarding the company’s ability to address revenue decline concerns from its blockbuster cancer drug, Revlimid, these won’t reflect in the first-quarter earnings this fiscal.
Continue Reading with
Continue Reading with
CNBC-TV18 Access Membership
Priority Access and Networking: CNBC-TV18’s flagship events
Interaction with CNBC-TV18’s journalists
Webinars & LIVE Q&As with India Inc. Leaders
Exclusive CNBC-TV18 studio & newsroom tours
Premium business insights, expert opinions & analysis
Curated lifestyle privileges & offers
